Although the relative importance of ecto-nucleotidases in TEX will likely vary among patients and may depend on the type of cancer, stage of cancer and exposure to therapeutic agents, the present results suggest that CD73, rather than CD39, inhibition might be a preferred mode of therapy in cancer patients. This evidence concerns the gene ENTPD1 and cancer.